Login to Your Account

Astrazeneca inks translational deal with Tianjin University

By Shannon Ellis
Staff Writer

Monday, May 19, 2014
SHANGHAI – In its third academic collaboration deal announced in China this year, Astrazeneca plc, of London, signed a translational research agreement with scientists from Tianjin Medical University (TMU) to explore novel targets for cardiac fibrosis, important in the area of cardiovascular disease (CVD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription